Abstract
Background The temporal relationship between Short-chain fatty acids (SCFAs) and hypertensive disorders of pregnancy (HDP) is unclear. This study aimed to examine the temporal and probable causal relationship between them.
Methods A nested case-control study including 387 pairs of cases with HDP and healthy controls was conducted. Seven SCFAs levels in plasma samples drawn at 16-20 gestational weeks before HDP were assayed by GC/MS. The individual and joint associations of SCFAs with HDP were examined by logistic regression and weighted quantile sum (WQS) regression, respectively, followed by two-sample bidirectional Mendelian randomization (MR) analysis to test the underlying causality.
Results The univariate model found each interquartile increase in plasma valerate was associated with a 32.1% (OR=0.679, 95%CI=0.546-0.844) reduction in the risk of HDP, a 29.4%(OR=0.706, 95%CI=0.548-0.910) reduction in the risk of gestational hypertension (GH) and a 39.1% (OR=0.609, 95%CI=0.397-0.935) reduction in the risk of preeclampsia/chronic hypertension with superimposed preeclampsia (PE/CH-PE). However, after adjustment for covariates, valerate was only associated with the risk of HDP (OR=0.699, 95% CI=0.516-0.946). In addition, plasma isobutyrate and hexanoate were associated with lower risks of HDP and PE/CH-PE. Furthermore, SCFAs co-exposure could reduce the risks of HDP and GH. MR showed that plasma acetate (OR=0.784, 95%CI=0.64-0.962), valerate (OR=0.575, 95%CI=0.363-0.909) and isovalerate (OR=0.642, 95%CI=0.428-0.963) had protective causal effects on GH. Meanwhile, plasma acetate had protective causal effects on PE (OR=0.746, 95%CI=0.6-0.927).
Conclusions The study suggested it is necessary to appropriately increase SCFAs levels during pregnancy to reduce the risk of HDP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (NO. 81903384), the Natural Science Foundation of Jiangsu Province (NO. BK20181438), the Scientific Research Project of Suzhou Gusu Health Fostering Talents Plan (NO. GSWS2021066), Science, Education and Health of Suzhou Youth Science and Technology Project (NO. KJXW2020073)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocols of this study were approved by the Ethics Committee of Soochow University (Approval NO. ECSU-2019000118)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used in the manuscript, code book and analytic code are available from the corresponding author on a reasonable request
